primary human dermal fibroblasts  (ATCC)

Journal: bioRxiv

Article Title: Potent broad-spectrum antiviral activity of the marine natural product Plitidepsin

doi: 10.64898/2026.02.24.707815

Figure Lengend Snippet: A549 cells or IMR90 human lung fibroblasts were pretreated with 5 nM Plitidepsin for 2 hours, then infected with ( A - C ), recombinant IAV-GFP, ( D - F ) VSV-GFP, or ( G , H ) HCMV-GFP at MOI 5. At 24 hpi, ( A , D , G ) percentage of GFP-positive cells and ( B , E , H ) mean GFP fluorescence intensity were quantified by flow cytometry. ( C , F ) Viral titers in culture supernatants were determined by plaque-forming assay, respectively. Data represent mean ± standard deviation from two independent experiments in triplicate. Viral titers are expressed as PFU/ml. Statistical analysis was performed using unpaired Student t-test. Significance levels: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant. ( I-K ) A549 or IMR90 cells were treated and infected as described above. At indicated time points post infection ( I ) IAV NS1, ( J ) VSV glycoprotein (G), and ( K ) HCMV CCH2-DDG9 protein levels were assessed by Western blot analysis using GAPDH as loading control.

Article Snippet: The following cell lines were used in this study: human dermal fibroblasts (HDFs, ATCC, Cat. # PCS-201-012); human microglial cells (HMC3, ATCC, Cat. # CRL-3304); human cervical adenocarcinoma cells (HeLa, ATCC, Cat. # CRM-CCL-2); African green monkey kidney epithelial cells (Vero E6, ATCC, Cat. # CRL-1 586); human hepatocellular carcinoma cells (Huh-7D12, Sigma-Aldrich, Cat. # 01042712-1VL); human lung adenocarcinoma cells (A549, ATCC, Cat. # CCL-185); and human lung fibroblasts (IMR-90, ATCC, Cat. # CCL-186).

Techniques: Infection, Recombinant, Fluorescence, Flow Cytometry, Standard Deviation, Western Blot, Control

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: 3D-bioprinted CAD file that was used to print the fibroblast construct. The final dome-shaped structure had a 1.0 cm diameter and six layers of fibers with an average width of ≈1.1 cm and a height of ≈0.7 cm (Aspect studio software, V1.2.59.0, Aspect Biosystems, Vancouver, BC, Canada).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Construct, Software

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Schematic showing 3D bioprinting of human fibroblasts with the antibiotic clindamycin in SiNPs and S. epidermidis . The same setup was used to test tetracycline-loaded SiNPs and S. aureus .

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques:

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: S. aureus bacterial fluorescence imaging using BacLight ® . Bacteria were imaged in LB broth after the addition of SiNP-loaded clindamycin 500 mg/mL: (a) green emission (live bacteria) and (b) red emission (dead bacteria). Fibroblast treatment of bare SiNPs: (c) green emission (live bacteria) and (d) red emission (dead bacteria). Untreated fibroblast constructs: (e) green emission (live bacteria) and (f) red emission (dead bacteria). Images (a–f) are from the same location with different fluorescence.

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Fluorescence, Imaging, Bacteria, Construct

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Imaging of 3D-bioprinted construct of fibroblasts infected with S. epidermidis (AH852) and treated with SiNP-loaded clindamycin 500 mg/mL under three conditions: pre-infection and pre-treatment (control group, with only fibroblasts 3D bioprinted), post-infection and pre-treatment (only S. epidermidis with GFP (green dots in the image) inoculation in the 3D-bioprinted construct, but with no treatment), and post-infection and post-treatment ( S. epidermidis with GFP (green dots in the image) inoculation in the 3D-bioprinted construct treated with SiNP-loaded clindamycin 500 mg/mL).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Imaging, Construct, Infection, Control

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Investigations in the “dermis” model of 3D-bioprinted construct inoculated with S. epidermidis and treated with SiNP-loaded clindamycin 500 mg/mL. (a) CFU counts in the pre-infection and pre-treatment condition, showing the higher S. epidermidis CFUs (before inoculating them in the 3D-bioprinted construct) than in the fibroblast HDFn media. (b) CFU counts in the post-infection and pre-treatment conditions show higher S. epidermidis growth over time. (c) CFU counts in the post-infection and post-treatment conditions highlight the effectiveness of SiNP-loaded clindamycin 500 mg/mL treatment against S. epidermidis in the 3D-bioprinted construct. (d) Growth curve of the S. epidermidis (AH852) showing its growth over time. (e) S. epidermidis bacterial imaging using BacLight® fluorescence detection. Bacteria were imaged in LB broth after the addition of SiNP-loaded clindamycin 500 mg/mL, green fluorescent protein (GFP): live bacteria (green dots in the image), Texas Red: dead bacteria (red dots in the image). The absence of red dots indicates that the SiNP-loaded clindamycin 500 mg/mL was an effective treatment against S. epidermidis in the 3D-bioprinted construct, in that it prevented the S. epidermidis from forming colonies or biofilms in the 3D-bioprinted construct. Images on (e) are the same spot with different fluorescence (one-way ANOVA and Tukey post-test; *: p < 0.05).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Construct, Infection, Imaging, Fluorescence, Bacteria